


# Business segment overviews

## Prescription

### Revenue (%)



**25%**

of Group revenue

- Africa Middle East
- Australasia
- Americas
- Asia
- Europe CIS

**36%**

of Group gross profit

- 45
- 39
- 25
- 6
- 6

### Key brands

| Eltroxin        | Imuran            | Lipitor        | Lyrca                         | Meticorten     | Purinethol |
|-----------------|-------------------|----------------|-------------------------------|----------------|------------|
| Thyroid hormone | Immunosuppressant | Cardiovascular | Anticonvulsant and neuropathy | Corticosteroid | Oncology   |



Products which generally require a prescription from a healthcare professional. Primary therapeutic areas are anti-inflammatories, immunosuppressants, hypothyroidism, anti-gout, analgesics, and corticosteroids.

|                         | 2024<br>R'million | 2023<br>R'million | % Change<br>Reported | CER |
|-------------------------|-------------------|-------------------|----------------------|-----|
| <b>Revenue</b>          |                   |                   |                      |     |
| Africa Middle East      | 4 242             | 3 876             | 9                    | 9   |
| Americas                | 2 832             | 1 801             | 57                   | 42  |
| Australasia             | 2 618             | 2 713             | (4)                  | (6) |
| Europe CIS              | 991               | 989               | —                    | (7) |
| Asia                    | 697               | 542               | 29                   | 24  |
| <b>Total</b>            | <b>11 380</b>     | 9 921             | 15                   | 11  |
| <b>Gross profit (%)</b> | <b>60,9</b>       | 60,7              |                      |     |

## Performance

Prescription brands achieved robust growth of 15%, with revenue reaching R11 380 million. This was primarily driven by the Americas, which posted a 57% increase supported by both organic and acquisition-led growth. Asia grew by 29%, benefiting from a 7% increase in organic growth alongside acquisitive gains. Africa Middle East, the largest region in this segment, reported strong organic growth of 9%. Europe CIS remained flat while Australasia experienced a 4% decline due to regulated price reductions in Australia.

The gross profit margin rose to 60,9% (FY2023: 60,7%), with the positive impact of the favourable sales mix more than offsetting the effects of regulated price cuts in Australia.

